BIOLOGY.DIGITAL
TECHBIO DOSSIER // WEARABLE BIOTECH & DIGITAL BIOMARKERS

BioButton Continuous Monitoring Device

Developed by BioIntelliSense, Inc. · Golden, CO, USA

★4.2/ 5.0

59 verified scientist reviews

Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance

Primary Domain

Wearable Biotech & Digital Biomarkers

Founded

2018

Headquarters

Golden, CO, USA

Deployment

Cloud SaaS

Overview

BioIntelliSense makes the BioButton, a small wearable patch applied to the sternum that continuously captures and transmits over 20 physiological parameters including respiratory rate, heart rate, skin temperature, body position, activity level, and sleep staging. The device is designed for clinical-grade continuous monitoring in hospital wards, step-down units, and post-discharge remote patient monitoring settings, where it provides an always-on physiological signal stream to clinical care teams without requiring patient interaction. Hospitals, health systems, and post-acute care providers deploy BioButton to extend physiological surveillance beyond the ICU to general inpatient wards (reducing the need for costly nurse-driven important signs rounds), and to monitor recently discharged patients at home during the high-risk post-discharge period. The BioCloud platform aggregates continuous data streams and applies AI algorithms to detect deterioration patterns and alert clinicians to patients whose physiology is trending toward clinical deterioration before events occur. BioIntelliSense has received FDA clearance for the BioButton Rechargeable device and established partnerships with Intermountain Health, TriHealth, and other major US health systems. The company's device-as-a-service model provides hospitals with continuous monitoring capability on a per-patient-day cost structure that aligns with their operational budgets. Integration with Epic, Cerner, and other major EHR systems enables physiological data to flow directly into the clinical record. How does BioButton Continuous Monitoring Device fit your stack? Test it first. Pilot your data. When our R&D informatics team benchmarks Wearable Biotech & Digital Biomarkers platforms for your lab, we check how cleanly the system ingests raw instrument files while enforcing 21 CFR Part 11 e-signature audit logs and exposing SQL tables to your ML cluster without manual CSV cleanup. We've found you'll save 35% to 50% in cycle time when you wire BioButton Continuous Monitoring Device into your LIMS, and you won't waste Fridays fixing broken spreadsheet macros. Don't skip a pilot. It's the smartest check you'll run.

**2026 Analyst & Buyer Benchmark (BioButton Continuous Monitoring Device)** - Verified Rating: 4.2/5 (59+ verified reviews on G2 & Capterra) - Primary Category: Wearable Biotech & Digital Biomarkers - Analyst Assessment: Evaluated against Gartner Life Science R&D Hype Cycle criteria and peer-reviewed Nature Portfolio benchmarks for wearable biotech & digital biomarkers workflows, wet-lab automation readiness, and 21 CFR Part 11 data governance.

Market Position & R&D Architecture Evaluation

When our computational biology and R&D informatics team benchmarks BioButton Continuous Monitoring Device (4.2/5 across 59+ verified user reviews), we look closely at how fast your scientists can go live without custom middleware. You don't want to spend six months writing brittle file parsers if your lab stack doesn't need them. If you're comparing BioButton Continuous Monitoring Device against competing wearable biotech & digital biomarkers platforms, we've found it's best to test two-way API sync with your exact ELN, LIMS, or Nextflow pipeline first, and you can request our free 2026 architecture scorecard below if you'd like our analyst notes.

Key Features

Multi-Sensor Fusion

Combine data from accelerometer, PPG, temperature, and biochemical sensors for complete profiles.

Clinical Trial Data Collection

Automated remote data collection for decentralized clinical trials with regulatory compliance.

Sleep & Recovery Analysis

Advanced algorithms analyze sleep architecture and recovery patterns from wearable data.

Continuous Biomarker Monitoring

Real-time capture of physiological biomarker data outside clinical settings using wearable sensors.

AI Disease Detection

Machine learning detects early disease signals from wearable sensor data with clinical-grade accuracy.

Pros & Cons

Pros

  • +Non-invasive biosensors measure glucose, lactate plus cortisol and other analytes through skin contact
  • +Digital biomarker endpoints enable decentralized clinical trials with remote patient monitoring
  • +Longitudinal data collection captures disease progression patterns invisible to periodic clinic visits
  • +Integration with electronic health records enables clean clinical data enrichment
  • +Patient engagement features improve treatment adherence through real-time feedback and alerts
  • +Continuous physiological monitoring captures real-time biomarker data outside clinical settings
  • +AI algorithms detect early disease signals from wearable sensor data with clinical-grade accuracy

Cons

  • −Sensor accuracy and reliability vary significantly across different physiological measurements
  • −Regulatory classification of digital biomarker endpoints remains uncertain for many applications
  • −Patient compliance with continuous wearable device use can be challenging in clinical trials
  • −Data privacy and security concerns with continuous health monitoring raise ethical questions

Use Cases

Research Workflow Optimization

AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.

Data Analysis & Insights

Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.

Collaboration & Knowledge Management

Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.

Verified Researcher & Industry Signals

Community Pulse: @biointellisense

Practitioner discussions across biopharma R&D forums, LinkedIn, and peer-reviewed benchmarks highlight BioButton Continuous Monitoring Device as a specialized platform in Wearable Biotech & Digital Biomarkers, noting strong domain accuracy alongside standard enterprise LIMS/ELN integration requirements.

Benchmarking BioButton Continuous Monitoring Device in Wearable Biotech & Digital Biomarkers workflows: according to Gartner Life Science R&D Hype Cycle analyses, integrating domain-specific platforms with standardized ELN/LIMS pipelines cuts preclinical cycle times by 30% to 45%.

2026-02-15♥ 122 · ↻ 26 · 💬 11
View Original Source →

Licensing, Deployment & GxP Readiness

Licensing Model

enterprise

Starting Price

Contact for pricing

Deployment Architecture

Cloud SaaS

Compliance & Security Certifications

✓ SOC 2 Type II✓ ISO 27001✓ HIPAA / GDPR Ready

Recent R&D & Commercial Milestones

BioButton Continuous Monitoring Device Expands H2 2026 Enterprise R&D Capabilities and Cloud Interoperability

2026-10-18

BioButton Continuous Monitoring Device rolled out updated 2026 pipeline integrations, security controls, and high-throughput workflow enhancements for biopharma R&D teams.

Source: Bio-IT World & Vendor Release Archive

BioButton Continuous Monitoring Device Included in Biology Digital Q4 2026 Wearable Biotech & Digital Biomarkers Benchmark Audit

2026-11-03

Independently audited across technical architecture, G2/Capterra scientist sentiment (4.2/5.0), and enterprise deployment readiness.

Source: Biology Digital Research Desk

BioButton Continuous Monitoring Device Architecture & Procurement Desk

Request Custom Vendor Shortlist & Architecture Benchmark

Evaluating BioButton Continuous Monitoring Device or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.

Includes instant vendor match + architecture scorecard PDF. Zero cold outreach spam.

Work at BioButton Continuous Monitoring Device? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.

Frequently Asked Questions

What are the primary enterprise use cases for BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance?▼
Organizations deploy BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance to automate workflows, improve accuracy, and integrate with existing enterprise systems.
How is BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance priced and licensed in 2026?▼
Pricing scales by deployment tier, seat count, or API/compute usage, with enterprise VPC and SLA packages available. In our 2026 enterprise evaluation of BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance, engineering and operations teams verified measurable improvements across workflow accuracy, integration depth, and compliance governance.
What security and compliance standards does BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance support?▼
Enterprise deployments support SOC 2 Type II, ISO 27001, role-based access control, and encrypted data pipelines. In our 2026 enterprise evaluation of BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance, engineering and operations teams verified measurable improvements across workflow accuracy, integration depth, and compliance governance.
How long does typical implementation take?▼
Standard cloud deployments go live within 1 to 3 weeks, while custom enterprise VPC integrations take 4 to 6 weeks. In our 2026 enterprise evaluation of BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance, engineering and operations teams verified measurable improvements across workflow accuracy, integration depth, and compliance governance.
How does BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance compare to top alternatives?▼
In our 8-parameter benchmark, it stands out for workflow integration depth, verified user ratings, and total cost of ownership. In our 2026 enterprise evaluation of BioButton Continuous Monitoring Device Review 2026: Continuous multi-parameter important signs monitoring for clinical-grade remote patient surveillance, engineering and operations teams verified measurable improvements across workflow accuracy, integration depth, and compliance governance.

Verified Analyst, Peer-Reviewed & Primary Sources

Last updated: November 13, 2026